Target Details
| UniProt AC | P35916 |
|---|---|
| Gene Symbol | FLT4 |
| Protein Name | Vascular endothelial growth factor receptor 3 |
| Organism | Homo sapiens |
| Entry Name | |
| Organism Category | Human |
| Pfam Domains | PF07679 (I-set) PF13927 (Ig_3) PF22971 (Ig_VEGFR-1-like_5th) PF07714 (PK_Tyr_Ser-Thr) PF21339 (VEGFR-1-like_Ig-like) PF17988 (VEGFR-2_TMD) PF22854 (VEGFR1-3_N_Ig-like) |
Summary
- Multi-target molecules 636
- Clinical molecules 169
- Avg pChEMBL 7.35
KEGG Pathways (10)
Associated Diseases (4)
Active Molecules (636)
| InChIKey | pChEMBL | Type | Targets | Clinical | |
|---|---|---|---|---|---|
WZBMMJKAHHOXRG
|
6.1 | Ki | 16 | — | |
KBJCTAIADOTYHC
|
6.1 | IC50 | 8 | Yes | |
KZMWAICISUWYLE
|
6.1 | IC50 | 7 | — | |
XISIJMIPHPQCQQ
|
6.1 | IC50 | 9 | — | |
GOQDBYBURLSMDX
|
6.0 | IC50 | 3 | — | |
QYUOZIXOUFDURP
|
6.0 | IC50 | 3 | — | |
SYSKFMGXKQRVAT
|
6.0 | IC50 | 3 | — | |
CJTQBCMGMLTHPI
|
6.0 | IC50 | 4 | — | |
FQQPROZCOUSSJP
|
6.0 | IC50 | 7 | — | |
NAOFTUMOMQMLEM
|
6.0 | IC50 | 3 | — | |
ZAEZEADQIGFKLO
|
6.0 | IC50 | 3 | — | |
BKGWUUYFDIOKHW
|
6.0 | IC50 | 3 | — | |
FVGFBWAPMMXCST
|
6.0 | IC50 | 3 | Yes | |
RAPSBRSLJYPUQC
|
6.0 | IC50 | 3 | — | |
CLRFYTGANQZOBS
|
6.0 | Ki | 41 | — | |
DLWMVUDMPMKGEE
|
6.0 | Ki | 24 | — | |
FJZXDUKUMALHNP
|
6.0 | Ki | 10 | — | |
FRHDZWLQTMKUPC
|
6.0 | IC50 | 11 | Yes | |
IVVSBEQDCAZLFY
|
6.0 | IC50 | 333 | — | |
KHVVJKLNKLQLJZ
|
6.0 | IC50 | 288 | — | |
KTRGYJLQTZDGPX
|
6.0 | Ki | 9 | — | |
LRZYYIZFBXFSJB
|
6.0 | Ki | 69 | — | |
MAHFVAHPQSLLJF
|
6.0 | IC50 | 288 | — | |
MASJMHFQMYAPJR
|
6.0 | Ki | 41 | — | |
OOXUOKDYYPUDQY
|
6.0 | IC50 | 2 | — | |
PJUVRETYCLPAFV
|
6.0 | Ki | 20 | — | |
RIBBPSYZBQQTQC
|
6.0 | Ki | 15 | — | |
SPYHMOFSJGTUNP
|
6.0 | Ki | 9 | — | |
SXMOIWLLBKAOGR
|
6.0 | IC50 | 2 | — | |
SYLTYCLPHHSEIJ
|
6.0 | Ki | 27 | — | |
UBLFSMURWWWWMH
|
6.0 | IC50 | 7 | — | |
VNGYQBMDQMDALH
|
6.0 | Ki | 25 | — | |
WCAKSXQRFBVWDG
|
6.0 | Ki | 10 | — | |
YEKVTSRZMPLPFK
|
6.0 | Ki | 17 | — | |
YHUIUSRCUKUUQA
|
6.0 | IC50 | 4 | Yes | |
YTIZDTKSGSSUMG
|
6.0 | Ki | 2 | — |